English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background: The Glucagon Like Peptide 1 (GLP1) recep-tor agonists are a new class for treatment of both type 2 diabetes and obesity.Aim of Study: To evaluate efficacy of GLP1 analogues in both weight reduction and glycemic control in obese Egyptians with and without diabetes.Patients and Methods: This intervention study was con-ducted from August 2017 to August 2018. Total of 40 patients were divided into 3 groups: Obese group, obese group with diabetes & obese group with diabetes after failure to lose 10% of their initial weight after bariatric surgery. Clinical data were collected, anthropometric measures and laboratory investigation included fasting blood glucose and HbA1c in the beginning and every 3 months for a year were done.Results: This study showed statistically significant body weight and BMI reduction in all groups, there was statistically significant reduction of fasting blood glucose, and HBA1c in the 2nd & 3rd group.Conclusion: GLP1 analogues are effective in treatment of obese patients with and without diabetes.

Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes